For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230608:nRSH1186Ca&default-theme=true
RNS Number : 1186C Hikma Pharmaceuticals Plc 08 June 2023
Notification and public disclosure of transactions by persons discharging
managerial responsibilities
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Douglas Hurt
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Market purchase of 1500 Ordinary Shares by Gillian Hurt, spouse of Douglas
Hurt
c) Price(s) and volume(s) Price(s): £18.20
Volume(s):1500
d) Aggregated information
- Volume
- Price 1500
£18.20
- Total £27,300
e) Date of the transaction 6 June 2023
f) Place of the transaction London Stock Exchange (XLON)
Helen Middlemist, Deputy Company Secretary
+44 (0) 20 7399 2760
8 June 2023
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGCGDLXDGDGXI